logo
Share SHARE
FONT-SIZE Plus   Neg

Optimer Pharma Names Hank McKinnell Chairman - Quick Facts

Optimer Pharmaceuticals (OPTR) announced that its board of directors has appointed Hank McKinnell as its new chairman. The company added that Kurt Hartman, who currently serves as General Counsel, chief compliance officer and senior vice president, has been appointed acting chief financial officer, or CFO, and that a search for a permanent CFO has commenced.

The company noted that the appointments were made after its board of directors removed Dr. Michael Chang as chairman and terminated John Prunty, CFO, and Dr. Youe-Kong Shue, vice president. The Board, excluding Chang, unanimously approved the personnel changes. Chang remains as a director of the company, but the Board has requested his resignation.

According to Optimer Pharma, the changes are not expected to materially impact its revenues or operations, including the commercialization and launch of DIFICID, but were related to certain lapses in corporate governance practices and the company's relationship with Optimer Biotechnology, Inc., its 43%-owned independent, Taiwanese-based affiliate.

Separately, Optimer Pharma stated that based upon preliminary results, it expects to report gross revenues of around $16.45 million for the first quarter of 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Dutch semiconductor equipment maker ASML Holding NV reported Wednesday higher profit in its third quarter as sales were boosted mainly with strong demand for DUV Systems. Meanwhile, margin declined. Looking ahead, the company projects sequentially lower sales in its fourth quarter. For fiscal 2017, the company maintained forecast for higher sales. Leaders of the Senate Health Committee revealed Tuesday they have reached an agreement on legislation to provide short-term stability to Obamacare. Committee Chairman Lamar Alexander, R-Tenn., and ranking member Patty Murray, D-Wash., announced the bipartisan agreement. Activist investor Rudolf Bohli is reportedly targeting Switzerland's second largest bank Credit Suisse. Bloomberg reported that Bohli has 0.2 percent stake in Credit Suisse that comes around 100 million francs or around $102 million.
comments powered by Disqus
Follow RTT